MarketPeel
Insider Trading Intelligence
FP

Frank Pasqualone

TBPH
SVP, CHIEF BUSINESS OFFICER · THERAVANCE BIOPHARMA, INC. · CIK 0001597334
FILING MIX · LIFETIME47%/53%
BUYS
7
SELLS
8
TOTAL VALUE
$1.55M
COMPANIES
2
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
456,206
AVG SELL PX
$20.60
TRADE KIND
SHOWING 15 / 15
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizonsHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Frank Pasqualone, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%+4.22%-2.92%+7.14%+7.14%
14d1+100.00%+4.39%-3.58%+7.97%+7.97%
30d1+0.00%-9.21%-1.65%-7.56%-7.56%
60d1+0.00%-34.21%+1.21%-35.42%-35.42%
90d1+0.00%-35.53%+6.46%-41.99%-41.99%
180d1+0.00%-49.12%+16.85%-65.97%-65.97%
1y1+0.00%-78.03%+28.08%-106.11%-106.11%
2y1+0.00%-97.25%+52.05%-149.30%-149.30%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
TBPH · 429,783 shares · as of Nov 19, 2021
0116,670233,340350,010466,6802021SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 7 buys / 8 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ENVB
ENVERIC BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
18,51826,423Jun 1, 2026Jun 3, 2026View →
ENVB
ENVERIC BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
7,6337,904Dec 23, 2025Dec 30, 2025View →
ENVB
ENVERIC BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
47,73348,733Oct 9, 2024Oct 11, 2024View →
ENVB
ENVERIC BIOSCIENCES, INC.
PURCHASE
1,000$2.14$2.1K1,000Sep 15, 2023Sep 19, 2023View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, CHIEF BUSINESS OFFICER
3,779$8.36$31.6K429,783Nov 19, 2021Nov 23, 2021View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, Chief Business Officer
3,779$14.05$53.1K433,562Aug 20, 2021Aug 24, 2021View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, Chief Business Officer
3,779$17.80$67.3K437,341May 20, 2021May 24, 2021View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, Chief Business Officer
26,961$18.79$506.6K439,719Feb 20, 2021Feb 23, 2021View →
TBPH
THERAVANCE BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
65,000466,680Feb 8, 2021Feb 10, 2021View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, Chief Comm Ops Officer
4,214$17.21$72.5K401,680Nov 20, 2020Nov 24, 2020View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, Chief Comm Ops Officer
4,214$18.22$76.8K405,894Aug 20, 2020Aug 24, 2020View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, Chief Comm Ops Officer
4,214$26.67$112.4K410,108May 20, 2020May 22, 2020View →
TBPH
THERAVANCE BIOPHARMA, INC.
SALE
SVP, Chief Comm Ops Officer
24,392$25.90$631.8K412,920Feb 20, 2020Feb 24, 2020View →
TBPH
THERAVANCE BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
65,000383,312Feb 3, 2020Feb 5, 2020View →
TBPH
THERAVANCE BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
54,000437,312Feb 3, 2020Feb 5, 2020View →
Other insiders · TBPH
Loading peer insiders…
About this filer
CIK 0001597334
ROLE
SVP, Chief Business Officer
PRIMARY
TBPH
COMPANIES
2
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001597334DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback